electroCore, Inc. (ECOR)
Market Cap | 26.40M |
Revenue (ttm) | 7.52M |
Net Income (ttm) | -21.32M |
Shares Out | 71.17M |
EPS (ttm) | -0.31 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 154,012 |
Open | 0.390 |
Previous Close | 0.364 |
Day's Range | 0.370 - 0.390 |
52-Week Range | 0.195 - 0.700 |
Beta | 0.93 |
Analysts | Buy |
Price Target | 2.51 (+576.73%) |
Earnings Date | Mar 8, 2023 |
About ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaw... [Read more]
Financial Performance
In 2021, electroCore's revenue was $5.45 million, an increase of 55.93% compared to the previous year's $3.50 million. Losses were -$17.22 million, -26.77% less than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ECOR stock is "Buy." The 12-month stock price forecast is $2.51, which is an increase of 576.73% from the latest price.
News

electroCore Announces Issuance of Two New U.S. Patents
ROCKAWAY, N.J., Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Offic...

gammaCore Sapphire™ Non-Invasive Vagus Nerve Stimulator (nVNS) Receives Unique National Product Code Number by the Belgian Pharmaceutical Association
ROCKAWAY, N.J., Nov. 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire has been...

electroCore to Participate at Canaccord Genuity MedTech and Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J., Nov. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan G...

electroCore Announces Third Quarter 2022 Financial Results
Third quarter 2022 revenue grew 33% over third quarter 2021

electroCore and Joerns Healthcare Partner to Expand Use Of gammaCore™ Vagus Nerve Technology for Headache Sufferers
ROCKAWAY, N.J. and CHARLOTTE, N.C.

electroCore Provides Select Third Quarter 2022 Financial Guidance
ROCKAWAY, N.J., Oct. 14, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary finan...

electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. Patents
Four patents issued expanding claims related to delivery of nVNS and other therapies using mobile devices Four patents issued expanding claims related to delivery of nVNS and other therapies using mob...

electroCore to Participate at Canaccord Genuity 42nd Annual Growth Conference
ROCKAWAY, N.J., Aug. 05, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan G...

electroCore to Announce Second Quarter 2022 Financial Results on August 4
ROCKAWAY, N.J., July 28, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the sec...

electroCore Provides Select Second Quarter 2022 Financial Guidance
ROCKAWAY, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided select unaudited preliminary finan...

electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID Syndrome
ROCKAWAY, N.J., July 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced Mayo Clinic is initiating an investigator-initiat...

electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain Centers
ROCKAWAY, N.J., May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus ne...

electroCore to Participate at Upcoming Investor Conferences
ROCKAWAY, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Executive Officer, Dan Go...

electroCore Announces Record First Quarter 2022 Financial Results
First quarter 2022 net sales of $1.9 million, approximately 58% over first quarter 2021 and 27% sequentially

electroCore Completes Sale of New Jersey Tax Benefits
ROCKAWAY, N.J., April 26, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has completed the sale of its available ...

electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in Neurology
ROCKAWAY, N.J., April 21, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frontiers in Neurology has published result...

gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) Program
ROCKAWAY, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore™ nVNS has been selected for furth...

electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New York
ROCKAWAY, N.J., March 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced its co-founder and Chief Medica...

electroCore to Present at 2022 Maxim Virtual Growth Conference
ROCKAWAY, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that electroCore's Chief Execut...

electroCore Announces Fourth Quarter and Full Year 2021 Financial Results
Full year 2021 net sales of approximately $5.5 million increased 56% over $3.5 million for full year 2020

electroCore Announces Changes to its Board of Directors
Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding significant marketing, media and brand strategy experience Julie Bruzzone Goldstein and Tricia Wilber to join the Board, adding sig...

electroCore to Present at 34th Annual Roth Conference
ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will b...

electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Treatment of Stroke Clinical Research Conducted on Non-invasive Vagus Nerve Stimulation (nVNS) for the Acute Tr...

ECOR Stock Alert: Why Is electroCore Soaring Today?
electroCore skyrocketed today after the FDA gave its PTSD treatment a breakthrough designation. ECOR stock closed up 60% on the news!

ElectroCore's Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress Disorder
The FDA has granted Breakthrough Designation to ElectroCore Inc's (NASDAQ:ECOR) gammaCore nVNS device for posttraumatic stress disorder (PTSD). The device showed a reduction of symptoms of PTSD by 31%...